GMED vs SGRY
Globus Medical vs Surgery Partners, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
SGRY
Surgery Partners, Inc.
48
Watch
| Metric | GMED | SGRY |
|---|
| AI Score |
71
|
48
|
| Price |
$85.12
|
$15.02
|
| P/E Ratio |
21.45×
|
-21.74×
|
| ROE |
11.8%
|
-4.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
21.4%
|
| Debt / Equity |
0.02×
|
2.40×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
42.3
|
| Beta |
0.954
|
1.937
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus SGRY.
GMED leads by 23 points.
GMED scores 71/100 (Buy) versus SGRY at 48/100 (Watch).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
SGRY Committee View
33% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -20.5% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price-to-book of 1.2x is a discount to asset value — Value
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- ROE of only -4.6% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.16 adds balance-sheet risk to the value case — Value
- Revenue declining -20.5% YoY -- this is not a growth story right now — Growth